Price
No data yet.
Social Signal Score
Analyst Ratings
24 analystsRevenue
$452.80M+124.38%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Carey Thomas Ford
- Sector
- Energy
- Industry
- Oil & Gas Drilling
- Employees
- 5,245
- Beta
- 1.26
- Country
- CA
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 1.23
Financials
Revenue
$452.80M+124.4%Net Income
$-1.20MEBITDA
$98.12M+110.3%Free Cash Flow
$69.20MEPS (diluted)
$-0.09Shares Outstanding (diluted)
13.41M-8.5%Operating Expenses
$26.45MCash & Debt
$66.29MReturn of Capital
$12.01MRevenue by Segment (annual)
$2.27MDividend per Share
$1.08Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.84B | $1.84M | $0.14 |
| 2024 | $1.90B | $111.19M | $7.81 |
| 2023 | $1.94B | $289.24M | $21.03 |
| 2022 | $1.62B | $-34.29M | $-2.53 |
| 2021 | $986.85M | $-177.39M | $-13.32 |
| 2020 | $734.50M | $-94.30M | $-8.76 |
| 2019 | $1.54B | $6.62M | $0.46 |
| 2018 | $1.54B | $-294.27M | $-20.05 |
| 2017 | $1.32B | $-132.04M | $-9.01 |
| 2016 | $951.41M | $-155.56M | $-10.61 |
| 2015 | $1.56B | $-363.44M | $-24.82 |
| 2014 | $2.35B | $33.15M | $2.20 |
| 2013 | $2.03B | $191.15M | $13.80 |
| 2012 | $2.04B | $52.36M | $3.80 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from PDS's reported EPS growth of -22.4% a year over 13 years. Historical EPS growth of -22% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.06
- Implied price
- $1.10
- Return from $84.91
- -58.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.55 — -99.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -25.0% | -65.9% | -64.3% | -63.0% | -61.8% | -60.8% |
| -20.0% | -63.6% | -61.9% | -60.5% | -59.3% | -58.2% |
| -15.0% | -61.3% | -59.6% | -58.0% | -56.7% | -55.6% |
| -10.0% | -59.0% | -57.2% | -55.6% | -54.2% | -53.0% |
| -5.0% | -56.8% | -54.8% | -53.1% | -51.6% | -50.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·6d ago·Neutral
Precision Drilling Corporation 2026 Third Quarter Results Conference Call and Webcast CALGARY, Alberta, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Precision Drilling Corporation (Precision) intends to release its 2026 third quarter results after the market closes on Tuesday, October 27, 2026, and has scheduled a conference call to begin at 11:00 a.m. MT (1:00 p.m. ET) on the next day, Wednesday, October 28, 2026.
View source ↗ - Newsglobenewswire.com·14d ago·Neutral
PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology 39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for PDS0101 PRINCETON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology…
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
Precision Drilling Announces Renewal of Normal Course Issuer Bid CALGARY, Alberta, Sept. 16, 2026 (GLOBE NEWSWIRE) -- This news release contains “forward-looking information and statements” within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the “Cautionary Statement Regarding Forward-Looking Information and Statements” later in this news release.
View source ↗ - Newsseekingalpha.com·24d ago·Neutral
Precision Drilling: U.S. Margin Recovery Could Drive A Rerating Precision Drilling (PDS) has strengthened its balance sheet, reduced debt, and operates a premium rig fleet with increasing activity, especially in Canada. Q2 revenue grew 11% to C$452.8M, but adjusted EBITDA fell 10% due to reactivation and upgrade costs, highlighting the need for margin recovery, particularly in the U.S. Contracted rigs in both Canada and the U.S. provide greater revenue visibility, but future margin improvement, …
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks Dr. Soon-Shiong will Join PDS Biotech's Board of Directors PDS Biotech Plans to Progress Development of PDS0301 Immunocytokine in Solid Tumors PRINCETON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today announced it has…
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
PDS Biotech Reports Second Quarter 2026 Financial Results PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today provided a business and clinical programs update and reported financial results for the quarter ended June 30, 2026.
View source ↗ - Newsbenzinga.com·55d ago·Negative
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program PDS Biotechnology Corporation (NASDAQ:PDSB) shares have fallen by about 67% on Tuesday as the company announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer.
View source ↗ - Newszacks.com·56d ago·Neutral
Will Lower PDS Margin Affect Aveanna Healthcare's Q2 Earnings? AVAH's Q2 revenues are expected to rise 9.8%, but lower PDS margins and higher costs may weigh on earnings.
View source ↗
Earnings
Tue, Oct 27(in 3 weeks)
Consensus estimate $1.48 per share
Typical surprise -45.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$-0.38 vs $0.43miss
- Wed, Apr 29$0.98 vs $1.73miss
- Wed, Feb 11$-2.34 vs $1.49miss
- Wed, Oct 22$-0.55 vs $1.06miss
- Tue, Jul 29$0.77 vs $-0.02beat
- Wed, Apr 23$1.53 vs $1.57miss
Estimates and results for PDS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Michael K. Simpsonhouse · ID02 · disclosed May 12, 2023 (849d later)Sell$1,001 - $15,000
- Michael K. Simpsonhouse · ID02 · disclosed Feb 1, 2021 (21d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.